Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Security

NVACW · Profusa, Inc.

NVACWOTCWarrantHistorical · closed Jul 11, 2025CIK 1859807Updated Sep 24, 2026

Company: Profusa, Inc.

Name history
NorthView Acquisition Corp · through Jul 15, 2025
Current security for this SEC filerPFSA · NASDAQ

NVACW price & chart

Provider market data
Historical security

This listing closed Jul 11, 2025. Live provider charts are shown only for current listings.

Current security: PFSA

About the company

Profusa was incorporated in the state of California on May 11, 2009 and operates as a digital health technology company based in Berkeley, California. The Company is engaged in the development of a new generation of biointegrated sensors that potentially empowers the individual with the ability to monitor their unique body chemistry. Profusa has invested over the last twelve years more than $100 million from sophisticated venture investors as well as the most sophisticated research institutions in the U.S. (including approximately $30 million from Defense Advance Research Projects Agency (“DARPA”) and the National Institutes of Health (“NIH”)) to develop a unique biosensor platform that is easily injected subcutaneously to provide, for the first time, real-time, individual biochemistry, that is cost effective while functioning for more than six times longer than known best in class solutions on the market today.

S-1/A · 2026-05-01 · 0001213900-26-050904

Company description from the cited filing.

Financials

FY 2025 · USD
Revenue · FY 2025
Net income-35,823,000USD · FY 2025
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Operating income-27,706,000USD · FY 2025
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Diluted EPS-107.01USD per share · FY 2025
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Some figures are unavailable for this reporting year.

balance sheet · annual statements
Line itemFY 2025FY 2024FY 2023FY 2022
ASSETS
AssetsUSD3,775,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

As of 2025-12-31

8,391,697
Source

10-K · 2025-03-31 · 0001013762-25-004396

As of 2024-12-31

10,884,675
Source

10-K · 2024-02-26 · 0001213900-24-016600

As of 2023-12-31

194,736,486
Source

10-K · 2023-03-06 · 0001213900-23-017591

As of 2022-12-31

Property, Plant and Equipment, NetUSD8,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

As of 2025-12-31

Current assets:
Cash and Cash Equivalents, at Carrying ValueUSD1,778,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

As of 2025-12-31

16,204
Source

10-K · 2025-03-31 · 0001013762-25-004396

As of 2024-12-31

4,519
Source

10-K · 2024-02-26 · 0001213900-24-016600

As of 2023-12-31

Assets, CurrentUSD3,764,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

As of 2025-12-31

60,862
Source

10-K · 2025-03-31 · 0001013762-25-004396

As of 2024-12-31

1,576,347
Source

10-K · 2024-02-26 · 0001213900-24-016600

As of 2023-12-31

511,704
Source

10-K · 2023-03-06 · 0001213900-23-017591

As of 2022-12-31

Prepaid Expense and Other Assets, CurrentUSD541,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

As of 2025-12-31

14,166
Source

10-K · 2025-03-31 · 0001013762-25-004396

As of 2024-12-31

6,750
Source

10-K · 2024-02-26 · 0001213900-24-016600

As of 2023-12-31

318,218
Source

10-K · 2023-03-06 · 0001213900-23-017591

As of 2022-12-31

Other Assets, NoncurrentUSD3,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

As of 2025-12-31

LIABILITIES AND EQUITY
LiabilitiesUSD30,433,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

As of 2025-12-31

13,011,056
Source

10-K · 2025-03-31 · 0001013762-25-004396

As of 2024-12-31

5,091,777
Source

10-K · 2024-02-26 · 0001213900-24-016600

As of 2023-12-31

1,830,478
Source

10-K · 2023-03-06 · 0001213900-23-017591

As of 2022-12-31

Stockholders’ equity:
Common Stock, Value, IssuedUSD519
Source

10-K · 2025-03-31 · 0001013762-25-004396

As of 2024-12-31

519
Source

10-K · 2024-02-26 · 0001213900-24-016600

As of 2023-12-31

519
Source

10-K · 2023-03-06 · 0001213900-23-017591

As of 2022-12-31

Additional Paid in CapitalUSD134,123,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

As of 2025-12-31

Retained Earnings (Accumulated Deficit)USD-160,781,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

As of 2025-12-31

-12,957,266
Source

10-K · 2025-03-31 · 0001013762-25-004396

As of 2024-12-31

-3,459,829
Source

10-K · 2024-02-26 · 0001213900-24-016600

As of 2023-12-31

-619,995
Source

10-K · 2023-03-06 · 0001213900-23-017591

As of 2022-12-31

Stockholders' Equity Attributable to ParentUSD-26,658,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

As of 2025-12-31

-12,956,747
Source

10-K · 2025-03-31 · 0001013762-25-004396

As of 2024-12-31

-3,459,310
Source

10-K · 2024-02-26 · 0001213900-24-016600

As of 2023-12-31

-619,476
Source

10-K · 2023-03-06 · 0001213900-23-017591

As of 2022-12-31

Liabilities and EquityUSD3,775,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

As of 2025-12-31

8,391,697
Source

10-K · 2025-03-31 · 0001013762-25-004396

As of 2024-12-31

10,884,675
Source

10-K · 2024-02-26 · 0001213900-24-016600

As of 2023-12-31

194,736,486
Source

10-K · 2023-03-06 · 0001213900-23-017591

As of 2022-12-31

Current liabilities:
Liabilities, CurrentUSD22,258,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

As of 2025-12-31

12,314,886
Source

10-K · 2025-03-31 · 0001013762-25-004396

As of 2024-12-31

4,921,477
Source

10-K · 2024-02-26 · 0001213900-24-016600

As of 2023-12-31

935,751
Source

10-K · 2023-03-06 · 0001213900-23-017591

As of 2022-12-31

Accounts Payable, CurrentUSD7,345,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

As of 2025-12-31

Deferred Income Tax Liabilities, NetUSD13,661
Source

10-K · 2024-02-26 · 0001213900-24-016600

As of 2023-12-31

Additional Financial Items
Accrued Liabilities, CurrentUSD5,981,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

As of 2025-12-31

684,483
Source

10-K · 2025-03-31 · 0001013762-25-004396

As of 2024-12-31

449,114
Source

10-K · 2024-02-26 · 0001213900-24-016600

As of 2023-12-31

Deferred Tax Liabilities, NetUSD36,940
Source

10-K · 2023-03-06 · 0001213900-23-017591

As of 2022-12-31

Redeemable Noncontrolling Interest, Equity, Common, Carrying AmountUSD1,565,078
Source

10-K · 2024-02-26 · 0001213900-24-016600

As of 2023-12-31

Lines labelled “Derived” are calculated from reported figures.

cash flow · annual statements
Line itemFY 2025FY 2024FY 2023FY 2022
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Share-based Payment Arrangement, Noncash ExpenseUSD891,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Changes in operating assets and liabilities:
Increase (Decrease) in Accounts PayableUSD3,560,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Deferred Income Tax Expense (Benefit)USD-5,529,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Net Cash Provided by (Used in) Operating ActivitiesUSD-16,248,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

-1,296,812
Source

10-K · 2025-03-31 · 0001013762-25-004396

2024-01-01 to 2024-12-31

-2,064,860
Source

10-K · 2024-02-26 · 0001213900-24-016600

2023-01-01 to 2023-12-31

-581,189
Source

10-K · 2023-03-06 · 0001213900-23-017591

2022-01-01 to 2022-12-31

Cash flows from investing activities:
Net Cash Provided by (Used in) Investing ActivitiesUSD-2,008,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

2,967,987
Source

10-K · 2025-03-31 · 0001013762-25-004396

2024-01-01 to 2024-12-31

185,599,914
Source

10-K · 2024-02-26 · 0001213900-24-016600

2023-01-01 to 2023-12-31

33,447
Source

10-K · 2023-03-06 · 0001213900-23-017591

2022-01-01 to 2022-12-31

Payments to Acquire Property, Plant, and EquipmentUSD8,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Cash flows from financing activities:
Payments for Repurchase of Common StockUSD3,248,878
Source

10-K · 2025-03-31 · 0001013762-25-004396

2024-01-01 to 2024-12-31

184,845,836
Source

10-K · 2024-02-26 · 0001213900-24-016600

2023-01-01 to 2023-12-31

Net Cash Provided by (Used in) Financing ActivitiesUSD19,843,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

-1,659,490
Source

10-K · 2025-03-31 · 0001013762-25-004396

2024-01-01 to 2024-12-31

-183,724,021
Source

10-K · 2024-02-26 · 0001213900-24-016600

2023-01-01 to 2023-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD1,778,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

As of 2025-12-31

16,204
Source

10-K · 2025-03-31 · 0001013762-25-004396

As of 2024-12-31

4,519
Source

10-K · 2024-02-26 · 0001213900-24-016600

As of 2023-12-31

193,486
Source

10-K · 2023-03-06 · 0001213900-23-017591

As of 2022-12-31

Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD296,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Income Taxes Paid, NetUSD1,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Additional Financial Items
Share-based Payment Arrangement, ExpenseUSD891,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Fair Value, Option, Changes in Fair Value, Gain (Loss)USD3,294,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Financing Interest ExpenseUSD2,574,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Gain (Loss) on Extinguishment of DebtUSD-3,378,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

General and Administrative ExpenseUSD24,902,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Income Tax Expense (Benefit)USD80,513
Source

10-K · 2025-03-31 · 0001013762-25-004396

2024-01-01 to 2024-12-31

456,790
Source

10-K · 2024-02-26 · 0001213900-24-016600

2023-01-01 to 2023-12-31

499,211
Source

10-K · 2023-03-06 · 0001213900-23-017591

2022-01-01 to 2022-12-31

InterestExpenseNonoperatingUSD2,521,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Investment Income, InterestUSD425,416
Source

10-K · 2025-03-31 · 0001013762-25-004396

2024-01-01 to 2024-12-31

2,248,538
Source

10-K · 2024-02-26 · 0001213900-24-016600

2023-01-01 to 2023-12-31

2,579,268
Source

10-K · 2023-03-06 · 0001213900-23-017591

2022-01-01 to 2022-12-31

Net Income (Loss) Attributable to ParentUSD-35,823,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

-8,711,619
Source

10-K · 2025-03-31 · 0001013762-25-004396

2024-01-01 to 2024-12-31

1,161,910
Source

10-K · 2024-02-26 · 0001213900-24-016600

2023-01-01 to 2023-12-31

7,167,738
Source

10-K · 2023-03-06 · 0001213900-23-017591

2022-01-01 to 2022-12-31

Noncash Merger Related CostsUSD500,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Nonoperating Income (Expense)USD-8,117,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

-7,280,068
Source

10-K · 2025-03-31 · 0001013762-25-004396

2024-01-01 to 2024-12-31

3,127,383
Source

10-K · 2024-02-26 · 0001213900-24-016600

2023-01-01 to 2023-12-31

Operating Costs and ExpensesUSD1,351,038
Source

10-K · 2025-03-31 · 0001013762-25-004396

2024-01-01 to 2024-12-31

1,508,683
Source

10-K · 2024-02-26 · 0001213900-24-016600

2023-01-01 to 2023-12-31

1,270,554
Source

10-K · 2023-03-06 · 0001213900-23-017591

2022-01-01 to 2022-12-31

Operating ExpensesUSD27,706,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Other Nonoperating Income (Expense)USD16,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Proceeds from Issuance of Common StockUSD-7,701,178
Source

10-K · 2023-03-06 · 0001213900-23-017591

2022-01-01 to 2022-12-31

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemFY 2025FY 2024FY 2023FY 2022
Operating Income (Loss)USD-27,706,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

-1,351,038
Source

10-K · 2025-03-31 · 0001013762-25-004396

2024-01-01 to 2024-12-31

-1,508,683
Source

10-K · 2024-02-26 · 0001213900-24-016600

2023-01-01 to 2023-12-31

-1,270,554
Source

10-K · 2023-03-06 · 0001213900-23-017591

2022-01-01 to 2022-12-31

Other Nonoperating Income (Expense)USD16,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD-8,631,106
Source

10-K · 2025-03-31 · 0001013762-25-004396

2024-01-01 to 2024-12-31

1,618,700
Source

10-K · 2024-02-26 · 0001213900-24-016600

2023-01-01 to 2023-12-31

7,666,949
Source

10-K · 2023-03-06 · 0001213900-23-017591

2022-01-01 to 2022-12-31

Income Tax Expense (Benefit)USD80,513
Source

10-K · 2025-03-31 · 0001013762-25-004396

2024-01-01 to 2024-12-31

456,790
Source

10-K · 2024-02-26 · 0001213900-24-016600

2023-01-01 to 2023-12-31

499,211
Source

10-K · 2023-03-06 · 0001213900-23-017591

2022-01-01 to 2022-12-31

Net Income (Loss) Attributable to ParentUSD-35,823,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

-8,711,619
Source

10-K · 2025-03-31 · 0001013762-25-004396

2024-01-01 to 2024-12-31

1,161,910
Source

10-K · 2024-02-26 · 0001213900-24-016600

2023-01-01 to 2023-12-31

7,167,738
Source

10-K · 2023-03-06 · 0001213900-23-017591

2022-01-01 to 2022-12-31

Earnings Per Share, BasicUSD per share-107.01
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

-1.47
Source

10-K · 2025-03-31 · 0001013762-25-004396

2024-01-01 to 2024-12-31

0.12
Source

10-K · 2024-02-26 · 0001213900-24-016600

2023-01-01 to 2023-12-31

0.3
Source

10-K · 2023-03-06 · 0001213900-23-017591

2022-01-01 to 2022-12-31

Earnings Per Share, DilutedUSD per share-107.01
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

-1.47
Source

10-K · 2025-03-31 · 0001013762-25-004396

2024-01-01 to 2024-12-31

0.12
Source

10-K · 2024-02-26 · 0001213900-24-016600

2023-01-01 to 2023-12-31

0.3
Source

10-K · 2023-03-06 · 0001213900-23-017591

2022-01-01 to 2022-12-31

Weighted Average Number of Shares Outstanding, Basicshares334,762
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

5,193,750
Source

10-K · 2025-03-31 · 0001013762-25-004396

2024-01-01 to 2024-12-31

5,193,750
Source

10-K · 2024-02-26 · 0001213900-24-016600

2023-01-01 to 2023-12-31

5,193,750
Source

10-K · 2023-03-06 · 0001213900-23-017591

2022-01-01 to 2022-12-31

Weighted Average Number of Shares Outstanding, Dilutedshares334,762
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

5,193,750
Source

10-K · 2025-03-31 · 0001013762-25-004396

2024-01-01 to 2024-12-31

5,193,750
Source

10-K · 2024-02-26 · 0001213900-24-016600

2023-01-01 to 2023-12-31

5,193,750
Source

10-K · 2023-03-06 · 0001213900-23-017591

2022-01-01 to 2022-12-31

Interest Expense (non-operating)USD2,521,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Additional Financial Items
Fair Value, Option, Changes in Fair Value, Gain (Loss)USD3,294,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Financing Interest ExpenseUSD2,574,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

General and Administrative ExpenseUSD24,902,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Interest Income, OperatingUSD8,937,503
Source

10-K · 2023-03-06 · 0001213900-23-017591

2022-01-01 to 2022-12-31

Investment Income, InterestUSD425,416
Source

10-K · 2025-03-31 · 0001013762-25-004396

2024-01-01 to 2024-12-31

2,248,538
Source

10-K · 2024-02-26 · 0001213900-24-016600

2023-01-01 to 2023-12-31

2,579,268
Source

10-K · 2023-03-06 · 0001213900-23-017591

2022-01-01 to 2022-12-31

Nonoperating Income (Expense)USD-8,117,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

-7,280,068
Source

10-K · 2025-03-31 · 0001013762-25-004396

2024-01-01 to 2024-12-31

3,127,383
Source

10-K · 2024-02-26 · 0001213900-24-016600

2023-01-01 to 2023-12-31

Operating Costs and ExpensesUSD1,351,038
Source

10-K · 2025-03-31 · 0001013762-25-004396

2024-01-01 to 2024-12-31

1,508,683
Source

10-K · 2024-02-26 · 0001213900-24-016600

2023-01-01 to 2023-12-31

1,270,554
Source

10-K · 2023-03-06 · 0001213900-23-017591

2022-01-01 to 2022-12-31

Operating ExpensesUSD27,706,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Other Operating IncomeUSD0
Source

10-K · 2023-03-06 · 0001213900-23-017591

2022-01-01 to 2022-12-31

Research and Development ExpenseUSD2,804,000
Source

10-K · 2026-04-15 · 0001213900-26-044046

2025-01-01 to 2025-12-31

Lines labelled “Derived” are calculated from reported figures.

Offerings

Registration 333-295364

S-1/A · 2026-05-01 · 0001213900-26-050904

Terms from the governing filing for this registration; not a claim that the offering is open today.

Filing attachments

ea030512101ex99-1.htm · 8-K · 2026-09-15

EX-99.1 2 ea030512101ex99-1.htm PRESS RELEASE DATED SEPTEMBER 14, 2026 Exhibit 99.1 Profusa, Inc. Receives Nasdaq Compliance Determination Berkeley, CA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the “Company”) announced today that on September 9, 2026, the Company received a letter (the “Compliance Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has demonstrated compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Pr

8-K · 2026-09-15 · 0001213900-26-099871

Read attachment ↗
ea030394501ex99-1.htm · 8-K · 2026-08-31

EX-99.1 2 ea030394501ex99-1.htm PRESS RELEASE Exhibit 99.1 Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement Berkeley, CA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the “Company”) announced that it has received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that on August 14, 2026, following the effectiveness of the Company’s 1-for-4 reverse stock split, the Company had

8-K · 2026-08-31 · 0001213900-26-095405

Read attachment ↗
ea030281201ex99-1.htm · 8-K · 2026-08-20

EX-99.1 2 ea030281201ex99-1.htm PRESS RELEASE Exhibit 99.1 Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of which $4.57 million was converted into Series A Convertible Preferred Stock Sufficient working capital obtained to fund operations for near term PCAOB audited 2024 and

8-K · 2026-08-20 · 0001213900-26-091905

Read attachment ↗
ea030001701ex99-1.htm · 8-K · 2026-07-31

EX-99.1 4 ea030001701ex99-1.htm PRESS RELEASE ISSUED ON JULY 31, 2026 Exhibit 99.1 Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs BERKELEY, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of an Option Agreement (the “Agreement”) which provides Profusa the right and option, but not the obligat

8-K · 2026-07-31 · 0001213900-26-084064

Read attachment ↗
ea029883201ex99-1.htm · 8-K · 2026-07-27

EX-99.1 2 ea029883201ex99-1.htm PRESS RELEASE DATED JULY 27, 2026 Exhibit 99.1 Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company BERKELEY, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of a non-binding term sheet with a privately held, commercial-stage health diagnostics and

8-K · 2026-07-27 · 0001213900-26-081560

Read attachment ↗
ea029713001ex99-1.htm · 8-K · 2026-07-06

EX-99.1 3 ea029713001ex99-1.htm PRESS RELEASE DATED JULY 2, 2026 Exhibit 99.1 Profusa Announces 1-for-25 Reverse Stock Split BERKELEY, California, July 02, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, today announced that it filed an amendment to its amended and restated certificate of incorporati

8-K · 2026-07-06 · 0001213900-26-075502

Read attachment ↗